LONDON (Thomson Financial) - Speciality biopharmaceutical company Vernalis PLC said the safety and efficacy results of the phase IIa trial of its diabetic neuropathy drug candidate, V3381, are “encouraging” and that the company looks forward to progressing V3381 into further clinical development.
